
Survodutide
Survodutide is an investigational once-weekly injection that acts on the GLP-1 and glucagon receptors. In a 76-week phase 3 trial, adults with obesity lost on average 12.2% to 13.0% of their body weight, compared with 5.4% on placebo, and in a heart safety trial of 5530 adults it did not raise the risk of heart events. It also cut liver fat in people with fatty liver disease. It is not FDA-approved, and about 1 in 5 people stopped it because of stomach side effects in the heart safety trial.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with obesity, type 2 diabetes or fatty liver disease who qualify for and choose to join a registered clinical trial; everyone else can ask a doctor about approved options
Common dosing range
No approved dose. Phase 3 trials raised the dose to 3.6 mg or 6.0 mg injected once weekly
When to expect effects
Liver fat measured at 48 weeks; weight loss measured at 46 to 76 weeks
Watch out for
Not FDA-approved and cannot be prescribed outside a trial; FDA has warned sellers of unapproved "research" survodutide. Nausea and vomiting were very common, and about 1 in 5 people stopped because of stomach side effects in the heart safety trial
What is it
Survodutide is an investigational drug that is not FDA-approved for any use, so it cannot be prescribed outside a clinical trial, and any product sold now as survodutide (including vials labeled "for research use only") is unapproved and unverified. FDA has warned companies that illegally sold unapproved drugs containing survodutide falsely labeled "for research purposes" or "not for human consumption" for human use. Its developer, Boehringer Ingelheim, is testing it as a once-weekly injection in phase 3 trials for obesity (the SYNCHRONIZE program) and for the liver disease MASH (the LIVERAGE trials). Phase 3 results in obesity, obesity with type 2 diabetes, fatty liver disease and heart safety were published in 2026; the liver trials and several others are still running on ClinicalTrials.gov.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
weight loss in adults with obesity without diabetes Good Evidence | -12.2% (3.6 mg) and -13.0% (6.0 mg) vs -5.4% on placebo at 76 weeks (SYNCHRONIZE-1) | Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes | Measured at 46 to 76 weeks |
weight loss in adults with type 2 diabetes Good Evidence | -8.2% (3.6 mg) and -9.8% (6.0 mg) vs -3.9% on placebo at 76 weeks | Adults with type 2 diabetes and a BMI of 27 or more | Measured at 76 weeks |
liver fat in fatty liver disease (MASLD) with obesity Good Evidence | 84.2% vs 24.3% reached at least a 30% reduction in liver fat (efficacy estimand); 68.5% vs 28.6% (treatment regimen estimand) | Adults with obesity and fatty liver disease with inflammation or scarring on tests | Measured at 48 weeks |
heart events (heart death, stroke, heart attack, artery-opening procedures or heart failure) Good Evidence | Hazard ratio 0.89 (95% CI 0.67 to 1.18): no increase in heart events, no proven reduction | Adults with obesity and established heart disease or high heart risk | Median 22 months of follow-up |
MASH (fatty liver inflammation) with liver scarring Limited Evidence | MASH improvement in 43% to 62% vs 14% on placebo | Adults with biopsy-confirmed MASH and fibrosis stage F1 to F3 | Measured at 48 weeks |
weight loss in adults with obesity without diabetes
- Effect
- -12.2% (3.6 mg) and -13.0% (6.0 mg) vs -5.4% on placebo at 76 weeks (SYNCHRONIZE-1)
- Best fit
- Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes
- Time
- Measured at 46 to 76 weeks
weight loss in adults with type 2 diabetes
- Effect
- -8.2% (3.6 mg) and -9.8% (6.0 mg) vs -3.9% on placebo at 76 weeks
- Best fit
- Adults with type 2 diabetes and a BMI of 27 or more
- Time
- Measured at 76 weeks
liver fat in fatty liver disease (MASLD) with obesity
- Effect
- 84.2% vs 24.3% reached at least a 30% reduction in liver fat (efficacy estimand); 68.5% vs 28.6% (treatment regimen estimand)
- Best fit
- Adults with obesity and fatty liver disease with inflammation or scarring on tests
- Time
- Measured at 48 weeks
heart events (heart death, stroke, heart attack, artery-opening procedures or heart failure)
- Effect
- Hazard ratio 0.89 (95% CI 0.67 to 1.18): no increase in heart events, no proven reduction
- Best fit
- Adults with obesity and established heart disease or high heart risk
- Time
- Median 22 months of follow-up
MASH (fatty liver inflammation) with liver scarring
- Effect
- MASH improvement in 43% to 62% vs 14% on placebo
- Best fit
- Adults with biopsy-confirmed MASH and fibrosis stage F1 to F3
- Time
- Measured at 48 weeks
Evidence for 5 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
weight loss in adults with obesity without diabetes
Disease adjunctIn SYNCHRONIZE-1, a phase 3 trial of 725 adults with obesity, or overweight with a weight-related condition, and without diabetes, once-weekly survodutide for 76 weeks lowered body weight by an average of 12.2% (3.6 mg) and 13.0% (6.0 mg), compared with 5.4% on placebo; 72.6% and 71.9% lost at least 5%, compared with 46.3% on placebo. These averages include people who stopped treatment. In the 46-week phase 2 trial of 387 adults, weight fell by 6.2% to 14.9% depending on dose, compared with 2.8% on placebo, but only 61% of those on survodutide (and 60% on placebo) completed the 46 weeks of treatment. Both trials were funded by Boehringer Ingelheim.
Bottom line: Meaningful weight loss over 76 weeks; no head-to-head trial against an approved drug has been published.
weight loss in adults with type 2 diabetes
Disease adjunctIn SYNCHRONIZE-2, a 76-week phase 3 trial of 752 adults with type 2 diabetes and a BMI of 27 or more (average HbA1c 7.4%), body weight fell by 8.2% (3.6 mg) and 9.8% (6.0 mg), compared with 3.9% on placebo. HbA1c fell by 0.9 and 0.8 percentage points, compared with 0.2 on placebo. The trial was funded by Boehringer Ingelheim and did not test diabetes complications.
Bottom line: People with type 2 diabetes lost less weight than people without diabetes in the companion trial.
liver fat in fatty liver disease (MASLD) with obesity
Biomarker supportIn SYNCHRONIZE-MASLD, a 48-week phase 3 trial in the United States and Spain, 216 adults with obesity and fatty liver disease with signs of inflammation or scarring received survodutide 6.0 mg weekly or placebo. Liver fat, measured by MRI, fell by at least 30% in 84.2% of people on survodutide, compared with 24.3% on placebo, among those who stayed on treatment (68.5% vs 28.6% counting everyone). The trial measured liver fat on scans, not liver failure, cirrhosis or survival, and its authors list the short duration as a limitation.
Bottom line: It clearly lowers liver fat; whether that prevents serious liver disease is still being tested.
heart events (heart death, stroke, heart attack, artery-opening procedures or heart failure)
No benefit foundSYNCHRONIZE-CVOT was a phase 3 heart safety trial of 5530 adults with obesity or overweight (BMI of 27 or more) and heart disease, kidney disease or several heart risk factors, followed for a median of 22 months. It measured a combined outcome of heart death, nonfatal stroke, nonfatal heart attack, procedures to open heart arteries and heart failure events. This occurred in 3.7% of people on survodutide and 4.1% on placebo (hazard ratio 0.89). The trial met its goal of showing that survodutide did not increase this risk, but the difference was too small to show a reduction: it was designed and analyzed as a safety trial, not to prove a heart benefit.
Bottom line: Reassuring on heart safety, but no evidence yet that it prevents heart attacks or strokes.
MASH (fatty liver inflammation) with liver scarring
Disease adjunctIn a 48-week phase 2 trial, 293 adults with biopsy-confirmed MASH and liver scarring (fibrosis stage F1 to F3) received survodutide 2.4, 4.8 or 6.0 mg weekly or placebo. Liver inflammation improved without worse scarring on repeat biopsy in 47%, 62% and 43%, compared with 14% on placebo. Scarring improved by at least one stage in 34% to 36%, compared with 22% on placebo. Phase 3 trials that measure liver outcomes (LIVERAGE) are still running.
Bottom line: Promising biopsy results in one phase 2 trial; phase 3 confirmation is pending.
How it works
How to take it
What to track
Bottom line: Solid weight loss and liver fat results with reassuring heart safety data, but high rates of nausea and vomiting, and not approved: a trial is the only legitimate route.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Stopping because of stomach side effects. In the heart safety trial, 19.3% (3.6 mg) and 20.8% (6.0 mg) stopped treatment because of stomach side effects, compared with 1.9% on placebo; in SYNCHRONIZE-MASLD, 19.9% vs 4.3% stopped because of stomach side effects. Serious adverse events were similar to placebo in the heart safety trial (20.8% to 22.5% vs 23.9%).
Deaths. In the heart safety trial, fatal adverse events occurred in 0.9% in each survodutide group and 0.6% on placebo, mostly from heart causes (0.3% to 0.4% vs 0.3%).
Class warning, not a finding for survodutide: approved drugs acting on the GLP-1 receptor carry a boxed warning because they caused thyroid C-cell tumors in rodents, and they are not used in people with a personal or family history of medullary thyroid cancer or MEN 2. Survodutide trials excluded these people.
Class warnings, not findings for survodutide: the labels of approved GLP-1 medicines warn of pancreatitis, gallbladder disease, dehydration leading to kidney injury, low blood sugar with insulin or a sulfonylurea, severe stomach side effects (not recommended with severe gastroparesis), serious allergic reactions, worsening of diabetic eye disease (retinopathy) in people with type 2 diabetes, a faster heart rate, and food entering the lungs during anesthesia or deep sedation. In SYNCHRONIZE-MASLD, no confirmed cases of acute pancreatitis or drug-induced liver injury occurred on survodutide.
Unapproved products of unknown quality. FDA has warned companies that illegally sold survodutide falsely labeled "for research purposes" or "not for human consumption" with dosing instructions for people, and says such products are of unknown quality and may be harmful.
Who should avoid it
- Anyone outside a registered clinical trial, because the drug is not approved and products sold outside trials are unapproved
- People with a personal or family history of medullary thyroid cancer or MEN 2, or with past pancreatitis (excluded from SYNCHRONIZE-1)
- People with a known stomach emptying disorder such as severe diabetic gastroparesis, or with severe (class IV) heart failure (excluded from SYNCHRONIZE-1)
- People who are pregnant, planning a pregnancy or breastfeeding: no human data are published, and labels of approved drugs in the class say they may cause fetal harm
Pregnancy & breastfeeding
Pregnancy: no data on survodutide in pregnancy are published. As a class warning, the labels of approved GLP-1 weight-loss drugs say they may cause fetal harm; the Wegovy label advises stopping semaglutide at least 2 months before a planned pregnancy. Breastfeeding: no data on survodutide in breast milk or in breastfed infants are published.
Interactions
Class-based, not a finding for survodutide: the Wegovy (semaglutide) and Zepbound (tirzepatide) labels say that use with insulin or an insulin secretagogue such as a sulfonylurea may increase the risk of low blood sugar, including severe low blood sugar, and that reducing the dose of the insulin or secretagogue may be necessary. Survodutide has no FDA label.
Class-based, not a finding for survodutide: survodutide acts on the GLP-1 receptor. The Wegovy label says use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended, and the Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended. SYNCHRONIZE-1 excluded people treated with obesity medicines in the 3 months before screening.
Class-based, not a finding for survodutide: the Zepbound label says tirzepatide delays stomach emptying and may affect the absorption of medicines taken by mouth, and says to monitor people taking oral medicines with a narrow therapeutic index (for example warfarin); the Wegovy label says to consider increased clinical or laboratory monitoring with such medicines. Published survodutide trials have not reported on this.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is survodutide FDA-approved?⌄
No. As of November 19, 2026, it does not appear among FDA's approved drugs, and FDA calls products containing it unapproved drugs. It is in phase 3 trials run by Boehringer Ingelheim for obesity and for the liver disease MASH. Only FDA can decide whether it is approved.
Is it legal to buy survodutide online?⌄
Survodutide is an unapproved drug. FDA has warned companies that illegally sold it falsely labeled "for research purposes" or "not for human consumption", and it urges people not to buy these products, which are of unknown quality and may be harmful. A registered clinical trial is the only legitimate way to receive it now.
How does survodutide compare with semaglutide or tirzepatide?⌄
Survodutide acts on GLP-1 like semaglutide, plus the glucagon receptor instead of tirzepatide's GIP receptor. In its main phase 3 obesity trial, average weight loss at 76 weeks was 12.2% to 13.0%. No head-to-head trial against semaglutide or tirzepatide has been published, so numbers from different trials cannot be compared directly.
Is survodutide safe for the heart?⌄
In a phase 3 heart safety trial of 5530 adults followed for a median of 22 months, heart events were not more common than with placebo (3.7% vs 4.1%). The trial was not designed to show a heart benefit, and it did not show one. Survodutide did raise heart rate slightly in another trial.
Can I take survodutide with my supplements or other medicines?⌄
No interaction studies of survodutide with supplements have been published. Based on the labels of approved GLP-1 medicines, low blood sugar is a risk with insulin or sulfonylureas, the labels say using it with another GLP-1 medicine is not recommended, and slower stomach emptying may affect medicines taken by mouth. Ask a doctor or pharmacist to check your own list.
References by claim
weight loss in adults with obesity without diabetes
weight loss in adults with type 2 diabetes
Wharton et al., 2026 · PubMed (2026) link
liver fat in fatty liver disease (MASLD) with obesity
Kaplan et al., 2026 · PMC (2026) link
MASH (fatty liver inflammation) with liver scarring
Sanyal et al., 2024 · PubMed (2024) link
heart events (heart death, stroke, heart attack, artery-opening procedures or heart failure)
Bozkurt et al., 2026 · PubMed (2026) link
Safety
Interaction: Insulin and sulfonylureas (such as glipizide, glyburide or glimepiride)
Zepbound (tirzepatide) prescribing information · DailyMed (FDA label) link
Track Survodutide with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
